Spironolactone use in hospitalized patients was associated with adverse reactions in 20.8%, primarily hyperkalemia (8.6%), which reached 42.1% with concurrent potassium chloride and BUN ≥50 mg/100 ml.
Observational (n=788)
What is the frequency and nature of adverse reactions to spironolactone in hospitalized medical patients?
Spironolactone use in hospitalized patients is associated with a high rate of adverse reactions, particularly hyperkalemia, which is strongly exacerbated by renal impairment and concurrent potassium supplementation.
Of 13,349 hospitalized medical patients monitored in a drug surveillance program, 788 (5.9%) received spironolactone during one or more admissions. Adverse reactions were attributed to spironolactone in 164 patients (20.8%). Hyperkalemia was reported in 68 patients (8.6%). Frequency increased with the level of blood urea nitrogen (BUN) and reached 20.3% in patients with BUN values of 50 mg/100 ml or greater. Hyperkalemia was far more common in patients who received potassium chloride concurrently (15.8%) than in those who did not (5.7%). Of patients with BUN values of 50 mg/100 ml or greater who received potassium chloride, 42.1% became hyperkalemic. Other adverse reactions were less common; dehydration (3.4%), hyponatremia (2.4%), gastrointestinal symptoms (2.3%), neurological disturbances (2.0%), and skin rashes (0.5%). The frequency of these events was not related to BUN levels.
D J Greenblatt (Mon,) conducted a observational in Hospitalized medical patients (n=788). Spironolactone was evaluated on Adverse reactions attributed to spironolactone. Spironolactone use in hospitalized patients was associated with adverse reactions in 20.8%, primarily hyperkalemia (8.6%), which reached 42.1% with concurrent potassium chloride and BUN ≥50 mg/100 ml.